543828 — Sudarshan Pharma Industries Income Statement
0.000.00%
Last trade - 00:00- IN₹2.91bn
- IN₹3.95bn
- IN₹4.64bn
- 39
- 39
- 86
- 57
Annual income statement for Sudarshan Pharma Industries, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 1,934 | 3,571 | 4,613 | 4,635 |
| Cost of Revenue | ||||
| Gross Profit | 141 | 192 | 304 | 411 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 1,866 | 3,464 | 4,462 | 4,394 |
| Operating Profit | 68 | 107 | 151 | 242 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 35.7 | 71.9 | 95 | 152 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 26.7 | 53 | 70.4 | 115 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 26.7 | 53 | 70.4 | 115 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 26.7 | 53 | 70.4 | 115 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 2.74 | 5.52 | 5.61 | 4.76 |
| Dividends per Share |